LeeW.M.. Medical management of acute liver failure. In: LeeW.M., WilliamsR., eds Acute liver failure.Cambridge: Cambridge University Press, 1997: 115–31.
2.
O'GradyJ.G., AlexanderG.L., HayllarK.M., WilliamsR.. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology1989; 97: 439–45.
3.
Chenard-NeuM.P., BoudjemaK., BernuauJ.Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure - a multicentre European study. Hepatology1996; 23: 1119–27.
DenisJ., OpolonP., NusinoviciV., GrangerA., DarnisF.. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut1978; 19: 787–93.
6.
O'GradyJ.G., GimsonA.E.S., O'BrienC.J., PucknellA., HughesR.D., WlliamsR.. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology1988; 94: 1186–92.
7.
RedekerA.G., YamahiroH.S.. Controlled trial of exchange-transfusion therapy in fulminant hepatitis. Lancet1973; II: 3–6.
8.
NagakiM., KimY.I., MikiK.Development and characterisation of a hybrid bioartificial liver using primary hepatocytes entrapped in a basement membrane matrix. Hepatology1996; 24: 435A.
9.
ShnyraA., BocharovA., BochkovaN., SpirovV.. Bioartificial liver using hepatocytes on biosilon microcarriers: Treatment of chemically induced acute hepatic failure in rats. Int J Artif Organs1991; 15: 189–97.
10.
DixitV., BigginsS., MartinP., ArthurM., GitnickG.. Controlled trials with the new UCLA bioartificial liver support device in animals with moderate to severe liver failure. Hepatology1996; 24: 436A.
SheilA.G., SunJ., MearsD.C.Preclinical trial of a bioartificial liver support system in a porcine fulminant hepatic failure model. Aust N Z J Surg1996; 66: 547–52.
NybergS.L., ShirabeK., PeshwaM.V.Extracorporeal application of a gel-entrapment, bioartificial liver: demonstration of drug metabolism and other biochemical functions. Cell Transplant1993; 2: 441–52.
15.
GerlachJ.C.. Development of a hybrid liver support system: a review. Int J Artif Organs1996; 19: 645–54.
16.
NaruseK., SakaiY., NagashimaI., JiangG.X., SuzukiM., MutoT.. Development of a new bioartificial liver module filled with porcine hepatocytes immobilised on non-woven fabric. Int J Artif Organs; 19: 347–52.
17.
JaureguiH.O., MullonC.J., TrenklerD.In vivo evaluation of a hollow fibre liver assist device. Hepatology1995; 21: 460–9.
KoideN., ShinjiT., TanabeT.Continued high albumin production by multicellular spheroids of adult rat hepatocytes in the presence of liver derived proteoglycans. Biochem Biophys Res Comun1989; 161: 385–91.
20.
LazarA., MannH.J., RemmelR.P., ShatfordR.A., CerraF.B., HuW.S.. Extended liver-specific functions of porcine hepatocyte spheroids entrapped in collagen gel. In Vitro Cell Dev Biol Anim1995; 31: 340–6.
21.
StangeJ., MitznerS.. Hepatocyte encapsulation - initial intentions and new aspects for its use in bioartificial liver support. Int J Artif Organs1996; 19: 45–8.
22.
CatapanoG.. Mass transfer limitations to the performance of membrane bioartificial liver support devices. Int J Artif Organs1996; 19: 18–35.
23.
KongL.B., ChenS., DemetriouA.A., RozgaJ.. Matrix-induced liver cell aggregates (MILCA) for bioartificial liver use. Int J Artif Organs1996; 19: 72–8.
24.
BaderA., KnopE., KernA.3-D coculture of hepatic sinusoidal cells with primary hepatocytes - design of an organotypical model. Exp Cell Res1996; 226: 223–33.
25.
RozgaJ., PodestaL., LePageE.A bioartificial liver to treat severe acute liver failure. Ann Surg1994; 219: 538–46.
26.
SussmanN.L., ChomgM.G., KoussayerT.Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology1992; 16: 60–5.
27.
RozgaJ., HolzmanM.D., Man-SooR.Development of a hybrid bioartificial liver. Ann Surg1993; 217: 502–11.
28.
WatanabeF.D., MullonCJ-P, HewittW.R.Clinical experience with a bioartificial liver in the treatment of severe liver failure. Ann Surg1997; 225: 484–94.
29.
SamuelD., IchaiP.H., FerayC.Treatment of patients with fulminant hepatitis with a bioartificial liver before liver transplantation. Hepatology1997; 26: 252A.
McCarthyM., EllisA.J., WendonJ.A.Use of extracorporeal liver assist device and auxiliary liver transplantation in fulminant hepatic failure. Eur J Gastroenterol Hepatol1997; 9: 407–12.
32.
EllisA.J., HughesR.D., WendonJ.A.Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology1996; 24: 1446–51.
33.
BaderA., KnopE., FruhaufN.Reconstruction of liver tissue in vitro: geometry of characteristic flat bed, hollow fibre and spouted bed bioreactors with reference to the in vivo liver. Artif Organs1995; 19: 941–50.
34.
BaderA., KnopE., BokerA.A novel bioreactor design for in vitro reconstruction of in vivo liver characteristics. Int J Artif Organs1995; 19: 368–74.
35.
FlendrigL.M., la SoeJ.W., JorningG.A.In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol1997; 26: 1379–92.
36.
StrainA.J.. Isolated hepatocytes: use in experimental and clinical hepatology. Gut1994; 35: 433–6.
37.
TakahashiM., MatsueH., MatsushitaM., NakajimaY., UchinoJ.. Isolation and culture of human hepatocytes from resected liver tissue as a bioreactor for a hybrid artificial liver. Artif Organs1993; 17: 653–9.
38.
OkamotoM., IshidaY., KeoghA., StrainA.J.. Evaluation of primary human hepatocytes co-cultured with the human hepatic stellate cell (HSC) line L190. Int J Artif Organs1997; 20: 509.
StangeJ., MitznerS.. Cell sources for bioartificial liver support. Int J Artif Organs1996; 19: 14–7.
41.
NybergS.L., PlattJ.L., ShirabeK., PayneW.D., HuW.S., CerraF.B.. Immunoprotection of xenocytes in a hollow fiber bioartificial liver. ASAIO J1992; 38: M463–7.
42.
BaquerizoA., MhoyanA., ShirwanH.Xenoantibody response of patients following treatment with a bioartificial liver. Transplantation Proceedings1997; 29: 964–65.
43.
PlattJ.L., BachF.H.. The barrier to xenotransplantation. Transplantation1991; 52: 937–47.
44.
KaufmanC.L., GainesB.A., IldstadS.T.. Xenotransplantation. Ann Rev Immunol1995; 13: 339–67.
45.
PatienceC., TakeuchiY., WeissR.A.. Infection of human cells by an endogenous retrovirus of pigs. Nature Medicine1997; 3: 282–6.
46.
AllanJ.. Silk purse or sow's ear. Nature Medicine1997; 3: 275–6.
47.
Courjault-GautierF., AntoineB., BensM.Activity and inducibility of drug-metabolising enzymes in immortalised hepatocyte-like cells (mhPKT) derived from a L-PK/Tagl transgenic mouse. Exp Cell Res1997; 234: 362–72.
48.
YanaiN., SuzukiM., ObinataM.. Hepatocyte cell lines established from transgenic mice harbouring temperature-sensitive simian virus 40 large T-antigen gene. Exp Cell Res1991; 197: 50–6.
49.
SchumacherI.K., OkamotoT., KimB.H., ChowdhuryN.R., ChowdhuryJ.R., FoxI.J.. Transplantation of conditionally immortalised hepatocytes to treat hepatic encephalopathy. Hepatology1996; 24: 337–43.
50.
HinoO., KitagawaT., NomuraK.Hepatocarcinogenesis in transgenic mice carrying albumin-promoted SV40 T antigen gene. Jap J Cancer Res1991; 82: 1226–33.
51.
KonoY., YangS., LetarteM., RobertsE.A.. Establishment of a human hepatocyte line derived from primary culture in a collagen gel sandwich culture system. Exp Cell Res1995; 221: 478–85.
52.
ArkadopoulosN., LujaH., SuhK.S.Transplantation of isolated hepatocytes prolongs survival and improves blood chemistry in anhepatic rats. Hepatology1997; 26: 252A.
53.
GuptaS., RajvanshiP., VasaS.R.G.Hepatocyte transplantation induces changes in the host liver suggestive of micro-circulatory deficits. Hepatology1997; 26: 251A.
54.
CristianoR.J., SmithL.C., KayM.A., BrinkleyB.R., WooS.L.. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilising a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA1993; 90: 11548–52.
55.
SkouterisG.G., SchroderG.H.. C-myc is required for the G0/G1-S transition of primary hepatocytes stimulated with a deleted form of hepatocyte growth factor. Biochem J1996; 316: 879–86.
56.
BlockG.D., LockerJ., BowenW.C.Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J Cell Biol1996; 132: 1133–49.
57.
NagakiM., ShidojiY., YamadaY.Regulation of hepatocyte genes and liver transcription factors in rat hepatocytes by extracellular matrix. Biochem Biophys Res Commun1995; 210: 38–43.
58.
PadghamC.R., BoyleC.C., WangX.J., RaleighS.M., WrightM.C., PaineA.J.. Alteration of transcription factor mRNA's during the isolation and culture of rat hepatocytes suggests the activation of a proliferative mode underlies their de-differentiation. Biochem Biophys Res Commun1993; 197: 599–605.
59.
RanaB., MischoulonD., XieY., BucherN.L.R., FarmerS.R.. Cell-extracellular matrix interactions can regulate the switch between growth and differentiation in rat hepatocytes: reciprocal expression of C/EBP alpha and immediate - early growth response transcription factors. Mol Cell Biol1994; 14: 5858–69.
